pharma · Breast Cancer · Prostate Cancer · UTHR
United Therapeutics Europe Ltd
United Therapeutics is a pharma organization headquartered in Silver Spring, USA. It trades on NYSE under ticker UTHR. Primary therapeutic focus areas include Breast Cancer, Prostate Cancer, Pulmonary Arterial Hypertensi
Phase 3 · small molecule · Fibromyalgia
Erenumab (AIMOVIG) is a monoclonal antibody developed by United Therapeutics Europe Ltd for fibromyalgia, a chronic pain disorder affecting millions globally. The program is currently in Phase 3 clinical development under internal code NMCP.2020.0010. Erenumab-aooe is administered via injection and targets calcitonin g
Internal code NMCP.2020.0010
Erenumab (AIMOVIG) is a monoclonal antibody developed by United Therapeutics Europe Ltd for fibromyalgia, a chronic pain disorder affecting millions globally. The program is currently in Phase 3 clinical development under internal code NMCP.2020.0010. Erenumab-aooe is administered via injection and targets calcitonin gene-related peptide (CGRP) pathways, a mechanism previously validated in migraine indications. The drug was first approved by the FDA in 2018 for migraine prevention under sponsor Amgen Inc (BLA761077). United Therapeutics' fibromyalgia program represents an expansion of the CGRP antagonist class into chronic pain conditions beyond migraine. The program reached its latest disclosed milestone on 14 August 2025, though specific details of that milestone are not yet disclosed. The Phase 3 trial NCT06411067 is registered and active in the clinical trial landscape.
Fibromyalgia affects approximately 2–4% of the global population, predominantly women, and remains characterized by widespread musculoskeletal pain, fatigue, and sleep disturbance with limited effective pharmacological options. Current standard-of-care therapies include pregabalin, duloxetine, and milnacipran—all with modest efficacy and tolerability concerns. The CGRP pathway has emerged as a validated target in pain neurobiology, with erenumab's mechanism offering potential differentiation from existing fibromyalgia treatments. Successful Phase 3 data would position erenumab as a novel biologic option in a market seeking alternatives to small-molecule analgesics and neuromodulators. The competitive landscape includes TNX-102 SL (Tonix Pharmaceuticals), sodium oxybate/Xyrem (Jazz Pharmaceuticals), and AXS-14/esreboxetine (Axsome Therapeutics), all in Phase 3 development for fibromyalgia. Market penetration by a CGRP monoclonal antibody would represent a significant shift in fibromyalgia treatment paradigms and could capture substantial commercial value in a chronic indication with high patient burden and limited satisfaction with existing therapies.
Drug Class: Monoclonal antibody targeting calcitonin gene-related peptide (CGRP).
Modality: Biologic (monoclonal antibody); classified as small_molecule in the database but functionally a large-molecule biologic.
Route of Administration: Subcutaneous injection.
Mechanism of Action: CGRP antagonism; mechanism of action details not yet disclosed in this profile.
Target: Calcitonin gene-related peptide (CGRP) pathway; specific target details not yet disclosed.
Related Therapies: Erenumab-aooe (AIMOVIG) was first approved by the FDA in 2018 for migraine prevention, establishing clinical proof-of-concept for CGRP monoclonal antibody efficacy in pain disorders.
Regulatory Status: FDA-approved for migraine (BLA761077, Amgen Inc sponsor); fibromyalgia indication remains investigational in Phase 3.
Also known as: fibromyalgia syndrome
A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.
ClinicalTrials.gov lists 67 registered studies for Fibromyalgia Syndrome (AACT aggregate).
Phase breakdown: NA (53), PHASE2 (8), PHASE3 (4), PHASE4 (2)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005546), Orphanet — fibromyalgia, NCT00222274, NCT00401830, NCT00436033, NCT00447083, NCT00464737, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
FDA approval for migraine
Erenumab-aooe (AIMOVIG) approved by FDA under BLA761077 for migraine prevention (Amgen Inc sponsor).
Phase 3 fibromyalgia trial ongoing
NCT06411067 is active in Phase 3 development for fibromyalgia indication under United Therapeutics Europe Ltd sponsorship.
Latest milestone
Most recent program milestone disclosed on 14 August 2025; specific details not yet disclosed.
The fibromyalgia development landscape includes multiple Phase 3 programs competing for market share. Tonix Pharmaceuticals' TNX-102 SL (2.8 mg and 5.6 mg formulations) is a small-molecule candidate in Phase 3. Jazz Pharmaceuticals' sodium oxybate (Xyrem) and placebo comparators are also in Phase 3 trials. Axsome Therapeutics' AXS-14 (esreboxetine), a norepinephrine reuptake inhibitor, is in Phase 3 development. The George Institute lists approved comparators including corticosteroid and local anesthetic combinations (KENACORT, lidocaine, bupivacaine formulations), representing current standard-of-care or adjunctive therapies. Erenumab's CGRP monoclonal antibody mechanism differentiates it from small-molecule neuromodulators and provides a biologic alternative to existing pharmacotherapy. The competitive advantage hinges on efficacy, tolerability, injection frequency, and payer acceptance of a biologic therapy in fibromyalgia—a chronic indication where cost-effectiveness and patient convenience are critical decision drivers.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| KENACORT 40 mg/ml sospensione iniettabile, Suero Fisiológico Braun 0,9% disolvente para uso parenteral Cloruro de sodio, Lidocaína B. Braun 20 mg/ml solución inyectable, BUPIVACAÍNA PHYSAN 0,25% SOLUCIÓN INYECTABLE | The George Institute | small_molecule | approved |
| TNX-102 SL Tablet, 2.8 mg | Tonix Pharmaceuticals Holding | small_molecule | phase_3 |
| TNX-102 SL Tablet, 2.8mg | Tonix Pharmaceuticals Holding | small_molecule | phase_3 |
| placebo | Jazz Pharmaceuticals Ireland Limited | small_molecule | phase_3 |
| Xyrem® | Jazz Pharmaceuticals Ireland Limited | small_molecule | phase_3 |
| Sodium Oxybate | Jazz Pharmaceuticals Ireland Limited | small_molecule | phase_3 |
| AXS-14 (Esreboxetine) | Axsome Therapeutics | small_molecule | phase_3 |
| TNX-102 SL Tablet, 5.6 mg | Tonix Pharmaceuticals Holding | small_molecule | phase_3 |
| TNX-102 SL Tablet 2.8 mg | Tonix Pharmaceuticals Holding | small_molecule | phase_3 |
| TNX-102 SL 2.8mg | Tonix Pharmaceuticals Holding | small_molecule | phase_3 |
| TNX-102 SL | Tonix Pharmaceuticals Holding | small_molecule | phase_3 |
| PREGABALIN | — | Voltage-gated calcium channel modulator | Approved |
| MILNACIPRAN HYDROCHLORIDE | — | Serotonin transporter inhibitor | Approved |
| LEVOMILNACIPRAN HYDROCHLORIDE | — | Norepinephrine transporter inhibitor | Approved |
| DULOXETINE HYDROCHLORIDE | — | Serotonin transporter inhibitor | Approved |
| TRAMADOL | — | Mu opioid receptor agonist | Phase 3 |
| SOMATROPIN | — | Growth hormone receptor agonist | Phase 3 |
| REBOXETINE | — | Norepinephrine transporter inhibitor | Phase 3 |
| OXYBATE | — | GABA-B receptor agonist | Phase 3 |
| MIROGABALIN | — | Voltage-gated calcium channel alpha2/delta subunit 2 modulator | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Erenumab-aooe (AIMOVIG) is FDA-approved for migraine prevention under BLA761077 (Amgen Inc sponsor, first approved 2018). The fibromyalgia indication is investigational; Phase 3 trial NCT06411067 is registered with the FDA.
European Medicines Agency (EMA): Regulatory status for fibromyalgia not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Program Status: The fibromyalgia program is currently terminated as of the latest data; however, the Phase 3 trial NCT06411067 remains registered. Termination rationale and timing are not yet disclosed. Regulatory pathway and approval timeline for fibromyalgia indication are not yet disclosed.
Erenumab-aooe (AIMOVIG) is FDA-approved for migraine prevention. United Therapeutics Europe Ltd is investigating erenumab for fibromyalgia treatment in Phase 3 clinical trials, though the program is currently terminated.
No. Erenumab is approved only for migraine prevention. The fibromyalgia indication remains investigational and the development program is terminated as of August 2025.
Erenumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a neuropeptide involved in pain signaling. By blocking CGRP, it reduces pain transmission in migraine and potentially other pain conditions.
Erenumab-aooe (AIMOVIG) was developed and is marketed by Amgen Inc for migraine. United Therapeutics Europe Ltd is sponsoring the fibromyalgia development program.
Erenumab is administered as a subcutaneous injection.
NCT06411067 is the Phase 3 trial evaluating erenumab for fibromyalgia under United Therapeutics Europe Ltd sponsorship. Results have not yet been reported.
Erenumab-aooe (AIMOVIG) was FDA-approved in 2018 for migraine prevention under BLA761077 (Amgen Inc sponsor).
The program is terminated as of August 14, 2025. The specific reasons for termination have not been disclosed.
Competing Phase 3 fibromyalgia programs include TNX-102 SL (Tonix Pharmaceuticals), sodium oxybate/Xyrem (Jazz Pharmaceuticals), and AXS-14/esreboxetine (Axsome Therapeutics).
Erenumab is a CGRP (calcitonin gene-related peptide) antagonist monoclonal antibody. Specific molecular details are not yet disclosed in this profile.
Erenumab is a monoclonal antibody, classified as a biologic therapeutic. It is a large-molecule protein, not a small molecule.
Fibromyalgia is a chronic pain disorder affecting 2–4% of the population, characterized by widespread musculoskeletal pain and fatigue. CGRP pathway involvement in pain signaling makes erenumab a candidate for fibromyalgia treatment, though the program is now terminated.
The internal program code is NMCP.2020.0010.
No partner is listed for the fibromyalgia program. United Therapeutics Europe Ltd is the sole sponsor.
Projected peak sales figures have not been disclosed for the fibromyalgia indication.
Regulatory status for the fibromyalgia indication in Europe (EMA), Japan (PMDA), and China (NMPA) has not been disclosed.
Erenumab → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: United Therapeutics' decision to pursue erenumab in fibromyalgia represents an off-label expansion of a validated CGRP antagonist into chronic pain beyond migraine. However, the program's terminated status as of the latest milestone (14 August 2025) suggests potential efficacy, safety, or commercial challenges that prompted discontinuation. The rationale for termination is not yet disclosed, limiting assessment of whether the decision reflects clinical futility, commercial repositioning, or resource reallocation.
Competitive Implications: Termination of the erenumab fibromyalgia program reduces competitive pressure on TNX-102 SL, sodium oxybate, and AXS-14 in Phase 3. If erenumab's termination reflects CGRP pathway limitations in fibromyalgia (distinct from migraine pathophysiology), it may inform competitive strategies for other CGRP programs in pain indications.
Future Catalysts: Publication of Phase 3 efficacy and safety data from NCT06411067 would clarify the clinical rationale for program termination. Regulatory guidance on fibromyalgia drug development and CGRP mechanism validation in chronic pain may emerge from competing programs' Phase 3 readouts.
Expected Milestones: No future milestones are currently disclosed for this terminated program.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.